Press releases

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in Stockholm, Sweden, on Monday, 6 February 2017 at 9:00 a.m. (CET)

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma was presented on poster P281 at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11

Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical trials within the next 12 months

Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients

Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma

Oncopeptides AB, a clinical stage company developing a peptidase potentiated therapy – melflufen – presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed refractory multiple myeloma. The results, presented at the American Society of Hematology, in Orlando, Florida showed an overall response rate (partial response or better) of 41% and clinical benefit rate (minimal response or better) of 56% in efficacy evaluable patients. At the date of analysis, the median progression-free survival was 9.4 months. Melflufen showed promising activity in heavily pre-treated RRMM patients where conventional therapies have failed and rates were similar across the different patient refractory status groups (single, double and triple refractory patients)

Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with Melflufen and Dexamethasone

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of melflufen and dexamethasone in patients with relapsed and relapsed refractory multiple myeloma will be presented on poster P285 at the 20 European Hematology Association Congress in Vienna, in June

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both granted Orphan Drug Designation to its lead candidate, melflufen, in the treatment of multiple myeloma